RxDoctor Payments Data

Tiffany Gregory, NP

Family · Spartanburg, SCNPI 1962936146

Payments from drug & device makers

$2,631in general payments, 2019–2025

Across 131 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$489
  • Abbott$405
  • Merck$273
  • Impulse Dynamics (USA) Inc.$242
  • AstraZeneca$214
  • Boehringer Ingelheim$210
  • plus $797 from 12 others

What the payments were for

  • Food & beverage$2,61099%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,631 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$5,489
Medicare patients
51
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan61$73,609
JardianceEmpagliflozin55$36,459
FarxigaDapagliflozin Propanediol43$34,883
EliquisApixaban25$28,284
Metoprolol Succinate82$1,157
Potassium Chloride39$1,152
Bumetanide39$1,018
Spironolactone140$829
Carvedilol91$760
Furosemide139$610
Atorvastatin Calcium73$484
Hydralazine Hcl26$456
Amiodarone Hcl11$407
Losartan Potassium34$289
ClopidogrelClopidogrel Bisulfate12$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$489$73,60961 claims
Boehringer IngelheimJardiance$210$36,45955 claims
AstraZenecaFarxiga$214$34,88343 claims
PfizerEliquis$109$28,28425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.

Other family in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →